BioAtla, Inc. (BCAB) Reports In-Line Q3 EPS

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/26/2026

1. ORCL
2. SPY
3. ANT
4. FFAI
5. FFR
6. LLY
7. TSLA
8. META
9. FICO
10. CART

Go back to BioAtla, Inc. (BCAB) Reports In-Line Q3 EPS

BioAtla Reports Third Quarter 2025 Financial Results and Highlights Recent Progress

November 13, 2025 4:05 PM EST

Company achieved FDA alignment on Phase 3 Oz-V trial for the treatment of 2L+ OPSCC, which will evaluate dual primary endpoints with potential of achieving accelerated approval followed by full approvalCompany is in advanced stages to finalize a strategic transaction with a potential partner and we remain on track to complete the transaction by year end
BA3182 trial in advanced adenocarcinomas is currently ongoing and evaluating various dosing and treatment schedules with a readout expected in the first half of... More